Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Janssen Sciences Ireland Unlimited Company has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 5 distinct examiners and 5 distinct art units, indicating separate reported examination settings.
LANKFORD JR, LEON B is the busiest examiner, with 1 pending matter. The data does not show repeated assignment to an examiner or art unit, so no portfolio-wide examiner pattern is established. Practitioners should evaluate each action in its own technical and examination context.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANKFORD JR, LEON B | 1 | 70.1% | +31.4% |
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| FERGUSON, JALISA HOLMES | 1 | 63.4% | +39.5% |
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.8% | +53.5% |
| GURLEY, JAMI MICHELLE | 1 | 50.0% | +19.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17596538 | Recombinant Interleukin 12 Construct and Uses Thereof | GURLEY, JAMI MICHELLE | 21d |
| 18858037 | FREEZE DRIED COMPOSITIONS | LANKFORD JR, LEON B | — |
| 18550323 | ANTIBACTERIAL COMPOUNDS | FERGUSON, JALISA HOLMES | — |
| 17621759 | METHODS OF TREATING HIV IN PEDIATRIC PATIENTS WITH RILPIVIRINE | RAMACHANDRAN, UMAMAHESWARI | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| 1623 | 1 |
| 1626 | 1 |
| 1627 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18858037 | FREEZE DRIED COMPOSITIONS | LANKFORD JR, LEON B | 1657 | §103 | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18705114 | IMIDAZOPYRIDINE AMIDES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | AGGARWAL, SAHIL CHANDER | 1623 | §112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18550323 | ANTIBACTERIAL COMPOUNDS | FERGUSON, JALISA HOLMES | 1626 | §112DP | Non-Final OA | — | Pending | Sep 13, 2023 |
| 17621759 | METHODS OF TREATING HIV IN PEDIATRIC PATIENTS WITH RILPIVIRINE | RAMACHANDRAN, UMAMAHESWARI | 1627 | §103Other | Non-Final OA | — | Pending | Dec 22, 2021 |
| 17596538 | Recombinant Interleukin 12 Construct and Uses Thereof | GURLEY, JAMI MICHELLE | 1647 | §103 | Non-Final OA | 21d | Pending | Dec 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJanssen Sciences Ireland Unlimited Company has 5 pending office actions as of November 2026, spread across 5 art units and 5 examiners.
Leon B Lankford Jr. has the most, with 1 of Janssen Sciences Ireland Unlimited Company's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.